Compare LPTH & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | GERN |
|---|---|---|
| Founded | 1985 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2011 | 1996 |
| Metric | LPTH | GERN |
|---|---|---|
| Price | $9.82 | $1.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $13.33 | $2.17 |
| AVG Volume (30 Days) | 3.4M | ★ 8.5M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,202,630.00 | $1,065,000.00 |
| Revenue This Year | $83.04 | $26.91 |
| Revenue Next Year | $24.83 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $5.83 | $1.04 |
| 52 Week High | $18.94 | $2.01 |
| Indicator | LPTH | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | N/A |
| Support Level | $8.96 | N/A |
| Resistance Level | $10.96 | N/A |
| Average True Range (ATR) | 0.58 | 0.00 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 56.64 | 0.00 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.